Enzo Biochem Files 8-K for Security Holder Vote

Enzo Biochem Inc 8-K Filing Summary
FieldDetail
CompanyEnzo Biochem Inc
Form Type8-K
Filed DateAug 19, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting

TL;DR

Enzo Biochem is calling for a shareholder vote. Big changes might be coming.

AI Summary

On August 19, 2025, Enzo Biochem, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not disclose the specific matters to be voted on or the date of the security holders' meeting.

Why It Matters

This filing indicates that Enzo Biochem is preparing for a shareholder vote, which could lead to significant corporate actions or changes in leadership.

Risk Assessment

Risk Level: medium — Shareholder votes can signal significant corporate events, such as mergers, acquisitions, or changes in governance, which carry inherent risks.

Key Players & Entities

  • Enzo Biochem, Inc. (company) — Registrant
  • August 19, 2025 (date) — Date of Report

FAQ

What specific matters will be submitted for a vote by Enzo Biochem's security holders?

The filing does not specify the exact matters to be submitted for a vote.

When is the meeting of security holders scheduled to take place?

The filing does not provide the date for the meeting of security holders.

What is the principal executive office address for Enzo Biochem, Inc.?

The principal executive office is located at 21 Executive Blvd., Farmingdale, New York 11735.

What is Enzo Biochem, Inc.'s telephone number?

The registrant's telephone number is (631) 755-5500.

What is the SIC code for Enzo Biochem, Inc.?

The Standard Industrial Classification code is 2836 for Biological Products (No Diagnostic Substances).

Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-08-19 15:35:45

Key Financial Figures

  • $0.01 — ch registered Common Stock, par value $0.01 per share ENZB OTC Markets OTCQX

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZO BIOCHEM, INC. By: /s/ Patricia Eckert Name: Patricia Eckert Title: Chief Financial Officer Date: August 19, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.